Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04745689
Title Study of AZD2811 + Durvalumab in ES-SCLC (TAZMAN)
Acronym TAZMAN
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP

Facility Status City State Zip Country Details
Research Site Grand Rapids Michigan 49503 United States Details
Research Site Cheongju-si 28644 Korea, Republic of Details
Research Site Jinju-si 52727 Korea, Republic of Details
Research Site Seoul 03722 Korea, Republic of Details
Research Site Seoul 06591 Korea, Republic of Details
Research Site Seoul 138-736 Korea, Republic of Details
Research Site Seoul 6351 Korea, Republic of Details
Research Site Bydgoszcz 85-796 Poland Details
Research Site Olsztyn 10-357 Poland Details
Research Site Poznan 60-693 Poland Details
Research Site Sevilla 41071 Spain Details
Research Site Valencia 46015 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field